Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: ACAN who wrote (20002)	10/31/2006 9:37:45 AM
From: Galirayo	Respond to of 23958

I'm not sure how that will affect the stock price. But it may eventually. [snip] The first poster, entitled "3-Month Interim Results (6-Month Study) on Safety and Efficacy of an Oral Insulin (Generex Oral-lyn(TM)) Administered at Lunchtime in Juvenile Type-1 Diabetes Mellitus Subjects Maintained on Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner Regular Insulin," was co-authored by Drs. Jaime Guevara-Aguirre, Marco Guevara-Aguirre and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR in Quito, Ecuador.